LinkedIn facebook twitter youtube
News archive
Recent news


The European Hematology Association (EHA) celebrates its Annual Meeting in Amsterdam, from 13 to 16 June. This is the most important congress of haematology in Europe in which latest developments and cutting-edge research in haematological diseases will be discussed. Find more information about the congress here.

For the first time, the session covering advocacy topics (both Patient Advocacy Track and EHA Advocacy Sessions) have been merged into the Joint EHA-Patient Symposium on Policy Challenges in Haematology.

The draft agenda is divided in two different days:

  • Thursday 13 June from 14 to 15:30: Join plenary session for all patient advocates. It will cover such as How to get the best of EHA, Determinants of medicines access (value, pricing, availability, affordability) or understanding what is valued in HTA. This session will be followed by diseases specific breakout sessions.
  • Saturday 15 June: the sessions will be divided in two parts:
    • Part I- 8:00 – 12:30. Part I will sessions on access to treatment (How to ensure patient access to innovation and affordability); the role of Patient-Reported Outcomes (PRO) in haematology and managing the hype on car t-cell therapy.
    • Part II – 14:45 – 17:15. It will include two sessions: regulating personalised medicine trials and raising the bar for drug approvals.

The agenda of the Joint EHA-Patient Symposium on Policy Challenges in Haematology may change. MPE will update this information and share the final agenda as soon as possible. Find the programme of the congress here.

MPE Advocate Development Programme (ADP)

As with every year, the MPE Advocate Development Programme (ADP) will celebrates its first face-to-face meeting during the EHA Annual Meeting. The meeting will have 3 different parts (the Joint EHA-Patient Symposium on Policy Challenges in Haematology and two separate meetings) plus the poster workshop session.

Six advocates from five different countries (Sweden, Hungary, Germany, Spain and Italy) joined the ADP to learn about clinical research and development in myeloma and AL amyloidosis, mechanisms of accessing diagnostics and drugs, interaction with stakeholders like clinicians and industry and the basics of evidence-based advocacy. Find more information here.

Recent news

» Join MPE's webinar on doctor and patients’ perspectives on myeloma CAR-T

» Study shows the importance of vaccination for myeloma patients

Leave a Reply

Your email address will not be published. Required fields are marked *

I accept the Privacy Policy